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Abstract
Background Several studies have associated elevated liver
enzymes (LFTs), obesity, and type 2 diabetes (T2DM), and
a link has been established between insulin resistance (IR)
and elevated ferritin concentrations. We examined the
relationship between LFTs, ferritin, and IR in morbid obese
subjects and the effect of weight loss after bariatric surgery.
Methods We measured liver enzymes, ferritin, insulin
resistance, and glucose tolerance (by OGTT) in 159 morbid
obese subjects (BMI=44.4±0.4 kg/m2) at baseline,
6 months and 1 year after laparoscopic-adjustable-gastric
banding (LAGB). Subjects were divided in two groups:
increased LFTs (ALT>30; AST/ALT<1) vs. normal LFTs.
Results A large proportion of morbid obese subjects had
increased LFTs (44%) which were associated with in-
creased IR and ferritin, suggesting potential liver disease. A
majority of the morbidly obese with increased LFTs, IGT,
and T2DM, were male and had almost double ferritin
concentrations, strongly correlated with ALT (r=0.43, p<
0.0001). Both ferritin and ALT correlated with waist
circumference and IR. One year after, LAGB glucose
tolerance improved, LFTs and IR were reduced; ferritin
did not change significantly, but was still correlated with
IR.
Conclusions Ferritin may be an additional useful marker
for more severe hepatic IR.
Introduction
Obesity and elevated liver enzymes are both independent
risk factors for the development of type 2 diabetes
(T2DM) [1, 2] and fatty liver disease (FLD) [3]. FLD
refers to a spectrum of disorders ranging from simple
hepatic steatosis to more severe manifestations, including
non-alcoholic steato-hepatitis (NASH), which can prog-
ress to fibrosis, cirrhosis, and liver failure [4, 5] and it is
associated to insulin resistance and to all the features of
the metabolic syndrome, such as dyslipidemia, hyperten-
sion, and hyperglycemia [6–8]. Thus, it is not surprising
that the great majority of obese subjects have FLD [3, 9,
10].
Recently, a link has been established between insulin
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ferritin may simply be another marker of insulin resistance
or whether elevated ferritin concentrations identify iron
stores that may contribute to the pathogenesis of altered
metabolic states. A recent study has suggested that body
iron contributes to excess oxidative stress already at non-
iron overload concentrations [11]. Moreover, serum
ferritin has been identified as an important and indepen-
dent predictor of the development of diabetes [12] and
high concentrations of ferritin, together with low oral
glucose insulin sensitivity, have been identified as inde-
pendent markers of fibrosis in NASH [13]. It has been
hypothesized that iron could be an important cofactor in
the pathogenesis and progression of some cases of
NASH [13] since FLD subjects have increased hepatic
fatty acid oxidation, and increased production of ROS
[14]. In a large cohort of NASH patients, 21.1% had
hyper-ferritinemia while only 7.4% had signs of pe-
ripheral iron overload and 9% had signs of hepatic iron
overload [13].
Considering the close relationship between obesity,
insulin resistance and development of FLD, we studied
their association with hepatic profile and ferritin concen-
trations. Since bariatric surgery-weight loss is associated
with reduced insulin resistance, restored glucose tolerance
[15, 16], reduced hepatic steatosis, and improved liver
enzymes [9, 10] we repeated the analyses after laparoscopic
gastric banding surgery to evaluate the impact of weight
loss on the association between hepatic profile, ferritin
concentrations, and insulin resistance.
Methods
Subjects
We analyzed, retrospectively, clinical and metabolic param-
eters in 159 morbidly obese patients (60% NGT; 22% IGT;
18% T2DM) consecutively recruited at the Istituto Clinico
Sant'Ambrogio, Ospedale San Paolo and Ospedale San
Raffaele, Milano, Italy (BMI=44.4+0.4 kg/m2). Eligibility
criteria have been described previously in detail [16, 17].
In all subjects, BMI, OGTT, and liver enzymes were
measured (ALT and AST). Subjects were considered to
have high liver function test (LFT) if ALT>30 and ratio of
AST/ALT<1. Measurements of ferritin, transferring, and
iron content were available in 127 subjects. High Ferritin
values (within normal range) were considered when
subjects where in the upper tertile, (i.e., >100 ng/ml in
women and >200 ng/ml in men).
Metabolic measurements All metabolic tests were per-
formed in the morning (0800 h) after a 10 to 12-h overnight
fast. For the OGTT, timed blood samples were collected for
the measurement of plasma glucose and insulin concen-
trations. Plasma glucose was measured by the glucose
oxidase reaction (Beckman Glucose Analyzer, Fullerton,
CA, USA). Plasma insulin concentrations were measured
by RIA using specific kits (Linco Research, St Louis, MO,
USA). Serum transaminases (alanine aminotransferase
[ALT] and aspartate aminotransferase [AST]), serum lipid
Table 1 Clinical and metabolic characteristics of the population before LAGB
Normal liver enzymes at baseline (n=89) High liver enzymes at baseline (n=70) pLiver enzyme
Gender (F/M) [% of M] 83/6 [7%] 49/21 [30%] <0.0001
[%NGT/IGT /T2DM] [% 65/20/15] [% 55/24/21] 0.003
Age (years) 42±1 41±1 ns
BMI (kg/m2) 43.6 ±0.6 44.6±0.8 ns
Waist (cm) 119±2 126±2 0.002
HbA1c(%) 6.2±0.1 6.5±0.2 ns
Fasting plasma glucose (mM) 5.9±0.2 6.3±0.3 ns
Fasting plasma insulin (mU/l) 15 [10–20] 18 [11–26] 0.02
Plasma total chol (mg/dl) 199[178–232] 202[179–226] ns
Plasma HDL chol (mg/dl) 49[41–56] 43 [37–53] 0.02
Plasma triglycerides (mg/dl) 121[92–159] 125 [89–202] ns
AST (U/l) 18 [16–21] 30 [23–41] <0.0001
ALT (U/l) 21 [17–25] 43 [36–58] <0.0001
Ferritin (ng/ml) 45 [21–90] 101 [47–174] <0.0001
Transferrin (mg/ml) 2.7±0.1 2.5±0.1 ns
Serum Iron (μg/dl) 76±3 88±4 0.02
Fibrinogen (mg/dl) 413±9 365±10 0.0007
Peripheral IS (OGIS) 7.0±0.2 6.4±0.2 0.02
Peripheral IS (Matsuda) 3.6±0.2 2.9±0.2 0.03
Hepatic IS (QUICKI) 316±3 308±3 0.02
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profile, ferritin, transferring, and iron content were deter-
mined by standard laboratory methods (normal ranges,
transferrin 200–400 mg/dl, ferritin women, 8–140 ng/ml,
men, 30–400 ng/ml).
Peripheral insulin sensitivity (IS) was assessed (1) by the
OGIS method [18], which estimates IS expressed as
glucose clearance during a euglycemic insulin clamp from
the plasma glucose and insulin profiles measured during the
OGTT; (2) by calculating IS as the Matsuda index [19]
which is an index of insulin resistance based on glucose
and insulin profiles during OGTT. These estimates have
been validated against the euglycemic insulin clamp
technique in normal, obese, and diabetic subjects [20]. We
also calculated the QUICKI index [21] which can be
considered an index of hepatic insulin sensitivity [22]
although it also correlates with the euglycemic insulin
clamp [21]. Since HGP is the primary determinant of the
fasting plasma glucose concentration [23], and the fasting
plasma insulin concentration is the primary regulator of
hepatic glucose production [24], the product of fasting
plasma glucose and FPI primarily reflects hepatic insulin
resistance.
Statistical analysis Data were given as the means±SEM for
normally distributed variables, while were expressed as
median and interquartile range (in square brackets) when
they had a skew distribution. Group differences according
to obesity and LFT were analyzed by two-way ANOVA
using log-transformed values of non-normally distributed
variables. The contribution of multiple factors to ALT and
ferritin concentrations was assessed by multivariate analysis
and partial correlation were reported.
Results
Baseline Study
Subjects were divided in two groups: normal or increased
LFTs (defined as AST/ALT<1 and/or ALT≥30 U/l). At the
time of enrolment, 44% of the subjects had increased liver
enzymes. High LFTs were associated with higher preva-
lence of IGT (24% vs. 20%) and T2DM (21% vs. 15%) and
with male gender (Table 1). Subjects with elevated liver
enzymes showed increased waist circumference, fasting
plasma insulin, HbA1c, and reduced HDL and insulin
sensitivity (Table 1).
Ferritin concentration was found almost double (al-
though within normal ranges) in subjects with high LFTs
compared with those with normal LFTs (101 vs. 45 ng/
ml, p<0.0001), that also had increased serum iron (88±4
vs. 76±3, p=0.02), while no difference was found for
transferrin (2.5±0.1 vs. 2.7±0.1 mg/dl, p=ns). On the
other hand, both hemoglobin and hematocrit were similar
in the two groups and within normal ranges (13.1±0.2
vs. 13.8±0.2, p<0.05; 38.9±0.5 vs. 40.3±0.6, p=ns,
respectively).
Fig. 1 Top panel correlations between ferritin and ALT concentra-
tions. Insulin sensitivity (calculated using OGIS) as a function of ALT
(central panel) and Ferritin (bottom panel) concentrations
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Before surgery, increased ALT values were signifi-
cantly correlated with larger waist circumference (r=
0.33), increased HbA1c (r=0.20) and insulin concentra-
tions (r=0.29) and reduced insulin sensitivity measured
either as QUICKI, OGIS, or Matsuda index (r=−0.28, r=
−0.32 and r=−0.30, respectively, all p<0.05). Ferritin
correlated positively with waist circumference (r=0.26),
HbA1c (r=0.22) and ALT concentrations (r=0.43) and
negatively with insulin sensitivity measured either as
QUICKI, OGIS index (r=−0.20, r=−0.30 and r=−0.22,
respectively, all p<0.05). We observed a strong relation-
ship between ALT and ferritin, even after accounting for
age, gender, BMI, and insulin sensitivity (Fig. 1). In a
multiple regression model, insulin sensitivity (OGIS)
correlated independently with ALT (partial r=−0.39, p=
0.0002), after accounting for age/gender/BMI (explaining
28% of OGIS variability).
Follow-up Study after LAGB
One year after surgery, mean weight loss was 21±1 kg,
BMI was 36.6±0.4 kg/m2 and waist circumference de-
creased by 15.2±0.8 cm. After LAGB both groups
decreased liver enzymes and 68% of the subjects with high
LFTs before surgery had normal LFTs. Both LFT groups
improved their OGTT profiles with a reduction in plasma
glucose and insulin concentrations and improved both
peripheral and hepatic insulin sensitivity; most of the
improvement was achieved during the first 6 months
(Table 2).The number of subjects that restored normal
glucose tolerance increased independently of changes in
liver enzymes (79% in the group with normal LFTs and
75% in the group that after 1 year still had high LFTs,
Fig. 2). However, subjects that started with increased LFTs
remained more insulin resistant than subjects with normal
LFTs (Table 2).
A slight decrease in ferritin concentration was observed
only in the normal LFT group (Table 2), but the
association between insulin resistance and ferritin concen-
tration (r=−0.20, p=0.02) was still present (Fig. 3). We
observed that subjects that after 1 year remained IGT or
T2D had higher ferritin concentrations (92 [112] vs. 49
[80] ng/ml, p=<0.01). The changes in insulin sensitivity
observed 1 year after LAGB were strongly correlated with
Fig. 2 Prevalence of NGT, IGT, and T2DM in the morbid obese
group before and 1 year after LAGB surgery
Table 2 Clinical and metabolic changes after LAGB
Normal liver enzymes at baseline (n=89) High liver enzymes at baseline (n=70)
Basal 6 months 12 months Basal 6 months 12 months
Weight (kg) 113±2 96±2* 93±2* 122±3 105±2* 102±2*
BMI (kg/m2) 43.6 ±0.6 37.0±0.6* 36.2±0.6* 44.6±0.8 38.3±0.8* 37.2±0.7*
Waist (cm) 119±2 106±1* 104±1* 126±2 113±2* 111±1*
HbA1c (%) 6.2±0.1 5.8±0.1* 5.6±0.1* 6.5±0.2 5.9±0.1* 5.8±0.1*
Fasting plasma glucose (mM) 5.9±0.2 5.3±0.1* 5.2±0.1* 6.3±0.3 5.2±0.2* 5.5±0.3*
Fasting plasma insulin (mU/l) 15 [10–20] 9 [7–12]* 9 [6–12]* 18 [11–26] 10 [7–16]* 10 [6–14]*
Plasma HDL chol (mg/dl) 49[41–56] 51 [44–60]* 55 [46–63]* 43 [37–53] 47 [39–55]* 49 [42–60]*
AST (U/l) 18 [16–21] 16 [14–19]* 16 [14–19]* 30 [23–41] 21 [17–26]* 21 [17–26]*
ALT (U/l) 21 [17–25] 16[13–21]* 18 [14–21]* 43 [36–58] 26 [21.31]* 24 [20–32]*
Ferritin (ng/ml) 45 [21–90] 38 [11–81]* 34 [17–73]* 101 [47–174] 72 [34–150]* 108 [56–156]




3.6±0.2 5.8±0.3* 6.4±0.3* 2.9±0.2 5.5±0.8* 6.0±0.6*
Hepatic IS
(QUICKI)
316±3 341±2* 346±3* 308±3 335±5* 342±4*
*p<0.05 vs. baseline (two-way ANOVA for repeated measurements)
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the improvement in BMI, body weight, and waist
circumference (r=−0.48, r=−0.46 and r=0.39, all p<
0.0001) but not with the changes in ALT or ferritin
(Table 3).
Discussion
The last decade has witnessed an epidemic increase in the
incidence of obesity [25], a major risk factor for the
development of fatty liver disease (FLD). Several studies
have associated elevated liver enzymes, obesity, and type 2
diabetes mellitus (T2DM) [2, 26, 27] and it has been
estimated that FLD occurs in >30% in obese subjects [3]
and in >60% of morbidly obese patients [9]. Recently, a
link has been established also between insulin resistance
and ferritin concentrations [5, 28]. We, thus, examined the
relationship between alanine aminotransferase (ALT), se-
rum ferritin concentrations and insulin resistance in a group
of morbid obese subjects and the effect of weight loss after
bariatric surgery on these parameters. We found that
subjects with increased liver function tests (LFTs) had
values of ferritin almost double of those with normal LFTs
although still within the normal range. A strong correlation
was observed between plasma ALT and ferritin concen-
trations, and between these two variables and increased
body mass index and insulin resistance. After bariatric
surgery there was a reduction in liver enzymes and insulin
resistance. Although the changes in ferritin concentrations
were mild, the correlation between ferritin and insulin
resistance was still present indicating ferritin concentration
as an additional useful marker for more severe (hepatic)
insulin resistance.
Serum ferritin is a widely used marker of total body iron
status in epidemiological studies and has been shown to
closely reflect body iron stores [29]. A syndrome of liver
iron overload was proposed [30], following an observation
that there was a higher prevalence of metabolic disorders
among patients with high ferritin, normal transferrin
saturation, and normal transferrin without genetic hemo-
chromatosis than among patients with genetic hemochro-
matosis; both groups had similar ferritin levels. The liver
iron overload syndrome shares features with the metabolic
or insulin resistance syndrome. The mechanisms of such an
Fig. 3 Top panel correlations between insulin sensitivity (calculated
using OGIS) and ALT concentrations before (black circles) and after
(white circles) LAGB. Bottom panel correlations between insulin
sensitivity (calculated using OGIS) and ferritin concentrations before
(black circles) and after (white circles) LAGB
Table 3 Matrix of Pearson's correlation coefficients between changes observed after bariatric surgery
Δ Body weight Δ BMI Δ Waist Δ Insulin sensitivity Δ QUICKI Δ ALTa Δ Ferritina Δ Triglyceridea
Δ Body weight – 0.98* 0.82* −0.46* −0.16* 0.22 0.20 0.16
Δ BMI 0.98* – 0.81* −0.48* −0.19* 0.21 0.17 0.14
Δ waist 0.82* 0.81* – −0.39* −0.19* 0.19 0.26* 0.21*
Δ insulin
sensitivity
−0.46* −0.48* −0.39* – 0.26* −0.05 −0.09 −0.10
Δ QUICKI −0.16* −0.19* −0.19* 0.26* – 0.12 −0.18 −0.08
Δ ALTa 0.22 0.21 0.19 −0.05 0.12 – 0.13 0.16
Δ Ferritina 0.20 0.17 0.26* −0.09 −0.18 0.13 – 0.19
Δ Triglyceridea 0.16* 0.14 0.21* −0.10 −0.08 0.16 0.19 –
*p<0.05
a Only subjects while elevated basal LFTs were included in this analyses
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association have not been identified, and it has been
hypothesized that the hyperinsulinemia of the metabolic
syndrome could be related to an accumulation of iron in the
liver [31] and thus involved in hepatic damage [14]. FLD
subjects have increased hepatic fatty acid oxidation and
increased production of ROS [32]. With regard to this, iron
is a transition metal capable of causing oxidative tissue
damage by catalyzing the formation of free radicals [33].
On the other hand, ferritin could be simply another
independent marker of insulin resistance [13]. In our group
of subjects, before bariatric surgery, ferritin concentrations
were increased proportionally to ALT concentrations,
although, in general, within normal ranges and similar in
NGT, IGT, and T2DM. A positive correlation was observed
between ferritin plasma concentrations and insulin resis-
tance, consistently with the recently proposed link between
iron load and insulin resistance [5, 28]. Bariatric surgery
induced weight loss has been shown to restore normal
glucose tolerance in T2DM and to improve hepatic function
[9] and also in this study liver enzymes decreased after
LAGB. After surgery, however, we did not observe a
significant decrease in plasma ferritin concentrations de-
spite the improvement in hepatic function and insulin
resistance. However, the correlations between ferritin,
ALT, and insulin resistance remained suggesting that
ferritin may simply identify a new phenotype of insulin
resistance. Consistent with this, a recent prospective study
showed that the incidence of the metabolic syndrome after
6 years was more than four-fold higher in subjects with
ferritin and transferrin values above the tertile compared
with participants with values below the bottom tertile
thresholds [28].
In conclusion, our results show in obese subjects have
increased plasma ferritin concentrations that are associated
with insulin resistance and elevated liver function tests
suggesting potential liver disease. Weight loss, achieved
with laparoscopic gastric banding, reduced liver enzymes
and insulin resistance, but it did not significantly change
ferritin that remained correlated with insulin resistance.
Thus, it is tempting to hypothesize that the dyed increased
liver enzymes and ferritin concentrations could be an
additional useful marker for hepatic insulin resistance and
greater cardiovascular disease risk.
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